{"id":"aezs-108-zoptarelin-doxorubicin","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Cardiotoxicity"},{"rate":null,"effect":"Alopecia"}]},"_chembl":{"chemblId":"CHEMBL3544954","moleculeType":"Protein","molecularWeight":"1893.04"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The zoptarelin moiety binds to GnRH receptors that are overexpressed on certain cancer cells, particularly ovarian and endometrial cancers. Upon receptor-mediated internalization, the doxorubicin payload is released intracellularly, allowing targeted chemotherapy delivery while potentially reducing systemic toxicity compared to free doxorubicin.","oneSentence":"AEZS-108 is a conjugate of a GnRH agonist (zoptarelin) linked to the chemotherapy drug doxorubicin, designed to deliver cytotoxic payload selectively to GnRH receptor-expressing cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:00:04.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer"},{"name":"Endometrial cancer"}]},"trialDetails":[{"nctId":"NCT01767155","phase":"PHASE3","title":"Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer","status":"COMPLETED","sponsor":"AEterna Zentaris","startDate":"2013-04","conditions":"Endometrial Cancer","enrollment":511},{"nctId":"NCT01698281","phase":"PHASE2","title":"Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer","status":"TERMINATED","sponsor":"AEterna Zentaris","startDate":"2012-12","conditions":"Breast Cancer","enrollment":7}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AEZS-108"],"phase":"phase_3","status":"active","brandName":"AEZS-108 / zoptarelin doxorubicin","genericName":"AEZS-108 / zoptarelin doxorubicin","companyName":"AEterna Zentaris","companyId":"aeterna-zentaris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AEZS-108 is a conjugate of a GnRH agonist (zoptarelin) linked to the chemotherapy drug doxorubicin, designed to deliver cytotoxic payload selectively to GnRH receptor-expressing cancer cells. Used for Ovarian cancer, Endometrial cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}